|Ms. Emma N. Walmsley||CEO & Director||N/A||N/A||1970|
|Mr. Simon P. Dingemans||CFO & Exec. Director||N/A||N/A||1964|
|Dr. Hal V. Barron||Chief Scientific Officer, Pres of R&D and Director||N/A||N/A||1963|
|Mr. Jack Bailey||Pres of US Pharmaceuticals||N/A||N/A||N/A|
|Ms. Karenann K. Terrell||Chief Digital & Technology Officer||N/A||N/A||1962|
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories primarily under the Sensodyne, parodontax, Poligrip, Voltaren, Panadol, Otrivin, and Theraflu brand names. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, pods, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, and malted drinks and foods. Its primary collaboration is with 23andMe; and strategic alliance is with Merck KGaA to jointly develop and commercialize M7824. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
GlaxoSmithKline plc’s ISS Governance QualityScore as of March 1, 2019 is 6. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 1; Compensation: 8.